VX-765 is an orally absorbed prodrug of VRT-043198, a potent and selective inhibitor of caspases belonging to the ICE/caspase-1 subfamily. VX-765 is converted to VRT-043198 under the action of plasma and liver esterases. The active metabolite of VX-765 e
产品名称:IL-转化酶/caspase-1抑制剂(VX-765) 英文名称:VX-765 产品货号:M04351 产品规格:1mL(10mM)|5mg|10mg|50mg|100mg VX-765是一种的IL-转化酶/caspase-1抑制剂,抑制IL-1β释放。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!
l)-pyrrolidine-2-carboxylicacid((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide(VX-765),an orallyavailableselectiveinterleukin(IL)-convertingenzyme/caspase-1inhibitor,exhibitspotent anti-inflammatoryactivitiesbyinhibitingthereleaseofIL-1betaandIL-18.JPharmacolExpTher ...
VX-765产品规格:1mL(10mM)|5mg|10mg|50mg|100mg发货周期:1～3天产品价格:询价本产品仅可用于科研实验,严禁用于其他非科研用途!VX-765是一种的IL-转化酶/caspase-1抑制剂,抑制IL-1β释放。注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!CAS号:273404-37-8别名:Belnacasan纯度:99.46%分子式:C24H33...
Belnacasan (VX-765, VX765)是VRT-043198的口服生物活性前药,一般被代谢为活性分子VRT-043198,是caspase-1选择性抑制剂,Ki值为0.8 nM。Caspase-1活化关键的炎性介质IL-1β,使其转换为有活性的分泌蛋白。Belnacasan可用于研究自身性炎症疾病,目前处于治疗银屑病和癫痫的II期临床试验中。
VX-765_Apoptosis_Caspase_CAS号273404-37-8说明书_AbMole中国
VX-765_有效的Caspase-1选择性抑制剂_273404-37-8_Apexbio
VX-765Patients with acute myocardial infarction receive a P2Y~(12)receptor antagonist prior to reperfusion, a treatment that has reduced, but not eliminated, mortality, or heart failure. We tested whether the caspase-1 inhibitor VX-765 given at reperfusion (a requirement for clinical use) can ...
VX765, a well-established inhibitor of caspase 1. VX765 robustly restrains caspase 1-mediated interleukin-1β production and gasdermin D processing. Our study assigned VX765 a novel role in antagonizing NLRP3 inflammasome assembly and activation. VX765 mitigates mitochondrial damage induced by ...
Caspase-1Ischemia/reperfusion injuryMyocardial infarctionP2Y12receptor antagonistVX-765Patients with acute myocardial infarction receive a P2Y12receptor antagonist prior to reperfusion, a treatment that has reduced, but not eliminated, mortality, or heart failure. We tested whether......